Should You Buy Rapt Therapeutics Inc (RAPT) Stock After it Is Lower By 6.46% in a Week?

The market has been down on Rapt Therapeutics Inc (RAPT) stock recently. RAPT gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Rapt Therapeutics Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on RAPT!

See Full RAPT Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With RAPT Stock Today?

Rapt Therapeutics Inc (RAPT) stock is up 7.28% while the S&P 500 is down -0.03% as of 1:53 PM on Wednesday, Mar 13. RAPT is higher by $0.58 from the previous closing price of $7.97 on volume of 385,957 shares. Over the past year the S&P 500 is higher by 34.17% while RAPT is down -67.87%. RAPT lost -$3.05 per share in the over the last 12 months.

More About Rapt Therapeutics Inc

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Click Here to get the full Stock Report for Rapt Therapeutics Inc stock.